$SKYE Cashflow Statement | Understand Stock

$SKYE

$1.45 -$0.12 (7.64%) Close

$SKYE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash, cash equivalents used in operating activities:
Finance charge from Sciences warrant modification
Write-down of vendor deposits
Depreciation and amortization
Net loss on disposal of asset
Stock-based compensation expense
Change in fair value of derivative liability
Amortization of debt discount
Change in estimate for legal contingencies
Gain from asset sale
Debt conversion inducement expense
Accrued interest conversion expense
Cost to acquire IPR&D asset
Foreign currency remeasurement gain
Changes in assets and liabilities:
Prepaid expenses
Prepaid expenses - related party
Other current assets
Other assets
Accounts payable
Accounts payable – related parties
Accrued interest – related party
Related Party
Nonrelated Party
Total accrued interest – related party

Accrued payroll liabilities
Other current liabilities
Other current liabilities - related parties
Operating lease liability
Net cash, cash equivalents used in operating activities
Cash flows from investing activities:
Proceeds from asset sales, net of legal expenses
Purchase of short-term investment
Purchases of property and equipment
Cash acquired in asset acquisition
Net cash, and cash equivalents used in investing activities
Cash flows from financing activities:
Proceeds from warrant exercises
Common Stock Warrants
Prefunded Warrants
Total proceeds from warrant exercises

Proceeds from convertible note - related party
Financing costs allocated to warrants issued with convertible debt
Purchase under employee stock purchase plan
Proceeds from option exercises
Proceeds from PPP loan
Proceeds from multi-draw credit agreement - related party
Repayment of loan payable
Proceeds from EHT bridge financing
Repayment of Amended Credit Agreement
Net cash, and cash equivalents provided by financing activities

Net increase in cash and cash equivalents
Cash, cash equivalents, beginning of year
Cash, cash equivalents, end of year
Cash paid during the year for:
Cash
Cash and cash equivalent
Restricted cash
Interest
Income taxes
Supplemental disclosures of non-cash financing activities:
Deferred issuance costs
Financing of insurance premium
Release of share liability
Common stock warrant exercises
Conversion of multi-draw credit agreement
Conversion of accrued interest due to related party
Right of use asset obtained in exchange for operating lease liabilities
Stock issued for assets
Purchases of property and equipment in other current liabilities
Release of share liability to additional paid-in-capital
Asset acquisition costs in other current liabilities and accounts payable
Conversion of convertible note - related party

Comments